Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Following a major outbreak involving the use of tear drops in 13 US states, experts are offering advice on how to protect dry eyes.
Read Full NewsCould timing prostate cancer radiotherapy according to patients’ circadian rhythm genes reduce the risk for late side effects?
Progression-free survival with the multitarget PAM inhibitor approaches 10 months after anti-CDK4/6 and aromatase inhibitor failure.
Researchers retrospectively analyzed outcomes for 50 patients with biopsy-proven monoclonal gammopathy of renal significance for a median follow-up of 6.15 years.
In a small single-center study, 1-year survival is 100% among carefully selected patients who undergo bilateral lung transplantation for stage IV disease confined to the lungs.
1.
Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?
2.
FDA Greenlights First Engineered Cell Therapy for a Solid Tumor
3.
Pivotal Studies in Double-Expressor DLBCL Yield Divergent Results
4.
Oncology Drug Shortages Persist, but Continue to Evolve
5.
Are patients with advanced cancer receiving treatment aligned with their goals?
1.
Unveiling Tumor Immunity: Pan-Cancer Proteogenomics Characterization
2.
Hematopoietic Aging Signatures and Future Hematologic Disease Risk
3.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
4.
Clinical Frameworks in Oncology and Quality Improvement
5.
Unlocking the Power of Neutrophils: Harnessing Their Disease-Fighting Potential
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.
2.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
3.
Efficient Management of First line ALK-rearranged NSCLC - Part II
4.
Current Scenario of Cancer- Final Discussion on the Importance of Genomic Testing & Advancement in Diagnosis and Treatment
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge